OROBORIUM
Confidential Investor Briefing

For qualified & sophisticated investors only

This material is private and confidential. It contains forward-looking projections and is provided for evaluation only — it is not an offer or solicitation of securities, and any investment is subject to definitive documentation and eligibility.

By entering, you confirm you are a qualified or sophisticated investor and agree to keep its contents confidential.

If you received this link in error, please close this page. © OROBORIUM 2026. All figures are illustrative projections, not guarantees.

Venture 01 — Phase 1

OROBORIUM

A premium medical hospitality platform built at the intersection of medical tourism, longevity science, recovery, and advanced preventative care.

Seed — SAFE
$3.5M
Phase 1 Opens
Apr 2027
Seed Return · 5-Yr
~2.4×
Property Yield
12%
An integrated system

Diagnosis. Treatment.
Recovery. Optimisation.

Structured as one continuous experience — not a collection of services. OROBORIUM eliminates the fragmentation that defines the current market.

Seminyak · Bali, Indonesia

Scroll
The Film
01
Opening Statement

The affluent patient is underserved everywhere.

International patients seeking high-level treatment, recovery, and performance optimisation currently face a fragmented market: clinical providers with limited hospitality value, luxury wellness brands with shallow medical depth, or recovery centres with disconnected services.

OROBORIUM addresses this gap by designing a new model — where medical expertise, hospitality, and lifestyle programming are integrated into a single, controlled environment with significantly stronger economics than Western markets.

The Opportunity

A proven market. A structural gap.

Medical tourism is a $100B+ category growing at approximately 15% annually. The fastest-growing segment — longevity, biohacking, and recovery — has yet to produce a credible, integrated hospitality operator at the premium tier.

Bali commands a unique position: Tier-1 international demand, significantly lower operating costs than Western markets, established medical infrastructure, and an existing culture of health-conscious travel. The Indonesian government is now actively investing in medical tourism infrastructure and has begun allowing international medical practitioners to operate domestically — a direct structural tailwind for OROBORIUM's model.

Medical-tourism market ~$35B (2024) heading toward ~$253B by 2034 at a double-digit CAGR (Precedence Research / Grand View Research); the wider wellness economy is $6.8T, forecast to $9.8T by 2029 (Global Wellness Institute, 2025) — with longevity & biohacking among its fastest-growing categories. Forward-looking; market figures are third-party estimates, not guarantees.

$100B+
Global medical tourism market
Growing at ~15% annually. The premium longevity and recovery segment remains largely unoccupied by integrated operators.
30–40%
Demand from Australia / New Zealand
The closest major outbound market for Bali, with established patient flow already active for cosmetic and elective surgery.
12% / yr
Property (SPV) target yield
8% preferred + up to 4% performance, asset-backed and senior to equity. No buyback obligation; liquidity via resale after Year 2.
<1 yr
Phase-1 clinic payback
A lean retrofit clinic (~$600K) opens April 2027 and is profitable in year one — fast proof, cash and credibility before the flagship is built.
The Project

One address. Every stage of care.

OROBORIUM is designed as an integrated medical hospitality system — not a clinic with rooms, not a spa with equipment. The architecture of the guest experience is built so that each touchpoint reinforces clinical trust and extends lifetime value.

The Phase 1 facility is located in Seminyak, Bali — operating as a retrofit, low-capex entry point with active clinic and hospital partnerships already secured.

For Phase 2 — the Kura Kura flagship — the site is the Kura Kura SEZ, a 498-ha special economic zone run by master developer BTID. A 25-year land lease (~$129K/yr) is being secured; land-first, before the build.

01
Medical Expertise
Protocols aggregated from the US, France, Switzerland, Dubai, and South Korea — benchmarked to international standards.
02
AI Integration
AI-driven systems embedded into diagnostics, treatment planning, and patient monitoring for precision and consistency at scale.
03
Hospitality Architecture
26 accommodation units — villas, pods, suites, and solo rooms — designed for different guest profiles within one facility.
04
Retention Model
High-margin add-on programs and membership structures that convert single visits into long-term patient relationships.
05
Impact Model
Local talent employment in healthcare and hospitality, plus subsidised access programs for the surrounding community — integrated into the business model.
Product Ecosystem

Six service verticals. One integrated stay.

Biohacking
Advanced IV Therapy ($115 avg.)
HBOT Hyperbaric Oxygen ($50 avg.)
Hormone Panel + Consultation ($300)
Red Light Therapy ($40 avg.)
AI Health Coaching Dashboard
Regenerative
Exosome Facial Treatment ($500)
PRP Therapy — Scalp / Face ($350)
EMS Training ($40 avg.)
Stem Cell Therapy — off-site affiliate
Diagnostics
Full Body Diagnostics + DEXA ($600)
Multi-Omics Profiling ($950)
Neurofeedback / Biofeedback ($110)
NAD+ High Dose IV ($195)
Aesthetics
Botox / Fillers — partner ($500)
Aesthetic Lasers / RF Devices
Glutathione IV Drip ($70)
Peptides + Custom Nutraceuticals ($950)
Recovery
Post-Surgery Inpatient Programs
Lymphatic Drainage + Scar Therapy
Infrared Sauna / Ice Bath / Hammam
Psychological Coaching ($125)
Accommodation
4 Luxury Villas — $250/night
4 Biohacking Pods — $440/night
4 Premium Suites — $250/night
4 Companion Family Villas — $450/night
10 Solo Rooms — $145/night
How It Works

Three guest profiles. One system.

Each profile enters the OROBORIUM environment through a distinct pathway — post-surgical referral, retreat booking, or day access — and is served within the same integrated clinical and hospitality framework.

Profile 01
Post-Surgery
Inpatient
10–21 night stays. 10–12 clients per month. High service utilisation of 10–15 treatments per stay. Surgical bookings are typically made 6–12 months in advance, providing OROBORIUM with forward visibility on bed demand before the patient arrives.
Profile 02
Biohacking
Retreat Guest
4–7 night packages. 50–60 clients per month. 6–10 services per stay. Core revenue driver. Attracted via performance optimisation and longevity positioning across international markets.
Profile 03
Day Pass /
Local Client
Single-day access. 60–80 clients per month. 1–4 services. Builds local credibility, fills capacity in lower-season periods, and feeds the referral and word-of-mouth pipeline.
Retention
Membership
& Protocols
Supplement protocols, remote health coaching, and membership programs convert departing guests into recurring revenue — extending lifetime value beyond the physical stay.
The Clinical Pathway

From first contact to ongoing optimisation.

Every guest moves through a structured clinical arc. The pathway is adapted by profile but follows the same underlying framework — ensuring care continuity, operational efficiency, and maximum lifetime value.

Post-Surgery Inpatient
10–21 nights
Pre-Arrival (weeks before)
Medical files received from referring surgeon. Health intake form completed. Dietary, mobility, and room requirements confirmed. Recovery program pre-built.
Day 1 — Intake Assessment
General physical with medical director. Bloodwork and vitals baseline. Pain, mobility, and wound assessment. Treatment plan confirmed.
Stay — Treatment Arc
Daily wound care and IV therapy. Lymphatic drainage and physiotherapy. Infrared sauna and gentle movement as cleared. Nutritional meal plan. Psychological support if requested.
Exit — Medical Interview
Discharge assessment with medical director. Recovery summary report prepared for referring surgeon. Supplement and home-care protocol handed over.
Post-Departure
AI health app follow-up: weekly check-ins, wound photo review, medication reminders. 30 / 60 / 90-day milestone reviews.
Biohacking Retreat Guest
4–7 nights
Pre-Arrival
Health goals questionnaire completed online. Wearable data (Oura / Whoop / Garmin) optionally synced to guest profile. Preferred treatment menu pre-selected.
Day 1 — Longevity Intake
Functional health assessment with longevity doctor. DEXA scan and full bloodwork panel. Performance and sleep baseline established. Personalised protocol issued.
Stay — Optimisation Arc
Daily biohacking sessions: HBOT, red light, IV therapy. Morning fitness with trainer. Nutrition protocol with chef. Optional aesthetics and regenerative treatments.
Exit — Results Review
Comparative biomarker review with longevity doctor. Personalised supplement protocol and lifestyle recommendations. Founding member or return-booking offer.
Post-Departure
AI health app tracking: sleep scores, HRV trends, protocol adherence. Quarterly remote consultation available. Membership upgrade presented.
Day Pass / Local Client
1 day
Booking
Online or partner-referred booking. Service menu selected in advance. Brief intake form completed. Day-use amenity access confirmed.
Arrival — Express Intake
Brief health check at reception. Vitals and contraindication screening for selected treatments. Guest profile created for future visits.
Day — Service Experience
Access to selected clinic services and day-use amenities (pool, hammam, sauna). F&B from OROBORIUM kitchen. Retail supplements and products available.
Exit — Conversion Moment
Brief debrief with wellness coordinator. Multi-treatment bundle offer. Stay package or membership presented. Referral program explained.
Post-Visit
Follow-up message with personalised recommendations. AI app onboarding offered. Loyalty discount for next visit or stay booking.
AI Continuity Layer
Across all three profiles, OROBORIUM's AI health platform maintains a persistent guest record — tracking biomarkers, treatment history, and protocol adherence before, during, and after each stay. This transforms one-time guests into long-term health relationships, increasing return visit rates and creating a compounding data asset for clinical refinement.
Value Creation

Three compounding value layers.

OROBORIUM is engineered for value across three distinct dimensions simultaneously — operational income, asset appreciation, and long-term brand equity. Each reinforces the others.

The Phase 1 entry model is deliberately lean: a low-capex retrofit operation that validates the concept, builds patient flow, and generates the evidence base needed to unlock the flagship development phase.

Layer 01 — Operating Income
The Phase-1 clinic is profitable in year one — revenue $1.0M → $2.4M and EBITDA $0.3M → $1.1M (2027–2029), payback under a year. The flagship adds $3.0M → $6.0M as it scales.
Layer 02 — Asset-Backed Yield
The 26 accommodation units are sold to property investors via per-unit SPVs at a 12%/yr target (8% preferred + up to 4% performance), senior to equity. No buyback obligation — liquidity via resale after Year 2, plus 30 nights' use a year.
Layer 03 — Brand & Network
Each validated phase extends the brand's licensing and franchise potential across Southeast Asia. The integrated system is the moat — replicable by design, difficult to replicate by execution.
Revenue Streams

Four distinct, complementary income lines.

$1.0→2.4M
Phase 1 · 2027 → 2029
Clinic & Services
The profit engine — treatments, amenity passes and outpatient visits. Year-round, forward-booked medical demand (not seasonal tourism). Scales to the majority of the flagship's $6.0M as Phase 2 comes online.
12% / yr
Funds the SPV yield
Accommodation
Room income across 26 keys at 58% → 80% occupancy pays the property investors' 12% yield. Year-3 room income covers the yield owed ~1.3×.
~$6.0M
Non-dilutive
Property (SPV) Pre-Sales
26 units sold to investors via per-unit SPVs ($100K–$480K each). This funds the room/villa build separately from the equity — the SAFE never pays for construction.
Recurring
Compounds
Helios AI & F&B
Membership ($9.99 basic / $49 clinical), on-site F&B and a meal-delivery line for Bali's fitness crowd — high-margin recurring revenue licensed arm's-length from Ateliersavant.
Traction / Progress

What is already in place.

Site & Infrastructure
Phase 1 site identified — Seminyak, Bali
Full architectural concept completed
Low-capex retrofit entry confirmed with clear scale path defined
Water, electrical, and infrastructure planning completed
Phase 2 land — Kura Kura SEZ, terms pending with master developer BTID
Clinical & Medical
Active clinic and hospital partnerships secured in Bali
International medical partnerships confirmed
Existing post-surgery patient flow from Bali and Australia — patients book their surgery 6–12 months in advance, providing forward demand visibility for recovery bed planning
Medical protocols benchmarked to US, France, Switzerland, Dubai, and South Korea standards
Commercial & Structural
Financial model validated across 5-year projections
Staffing model structured — 25 roles defined
SPV accommodation investor structure prepared
Staged capital deployment framework in place
Medical Partner Equity Programme designed — equity participation for referring physicians worldwide
Go-To-Market

Five acquisition channels. One cohesive position.

The go-to-market strategy is built around referral density and positioning credibility — not advertising volume. Each channel reinforces the clinical authority of the brand.

Medical Referrals
Hospital and surgical partner networks in Bali and Australia direct post-operative patients into OROBORIUM's recovery program. Existing patient flow is already active. Patients book surgery 6–12 months ahead, providing forward bed demand visibility.
Medical Partner Equity Programme
Respected doctors worldwide can earn a small equity stake from a reserved pool (capped at ~8%, tiered by influence, performance-vested against referred revenue). This allows participating doctors to refer patients to "their longevity clinic in Bali" — aligned, high-trust referral relationships that are difficult for competitors to replicate, and that cost the P&L nothing because they're self-financing through the patients they bring.
Medical Tourism Platforms
Listed partnerships with established medical tourism aggregators targeting the US, European, and Southeast Asian markets.
Longevity & Performance Community
Targeted positioning in biohacking, longevity, and performance optimisation communities — the primary demand driver for the 4–7 night retreat segment.
Influencer Residency Programme
When occupancy reaches 80%, OROBORIUM reserves approximately 15% of available capacity for hosted influencer stays — offered at cost or complimentary. This maintains a constant flow of organic content and user-generated coverage year-round, functioning as a systematic content engine rather than a conventional media budget. Services are offered at cost; stays are complimentary at qualifying occupancy thresholds.
Source Markets
Australia / NZ
35%
Southeast Asia
20%
USA / Canada
18%
Europe
18%
Other
8%
Occupancy-Based Communication Logic
At 80%+ occupancy, ~15% of capacity is allocated to the Influencer Residency Programme. Below 80%, that capacity returns to commercial bookings. This dynamic allocation ensures the programme is never a cost centre — only deployed when operational headroom exists.
Ramp-Up Assumption
Months 1–3: 50–60% of target capacity. Months 4–6: 70–80%. Months 7–12: 90–100%. Conservative ramp ensures projections remain grounded.
Competitive Positioning

Where OROBORIUM sits in the market.

The competitive landscape consists of three existing categories — each with a structural limitation that OROBORIUM is designed to resolve.

Capability OROBORIUM Luxury Wellness Clinical Providers Recovery Centres
Integrated medical + hospitality
Clinical-grade diagnostics on-site
AI-assisted treatment protocols
International medical partnerships
Premium accommodation on-site
Longevity / biohacking services
Post-surgery recovery protocols
Physician equity referral programme
Investor property ownership structure

● Full capability  ◐ Partial  ○ Absent

Financial Overview

The numbers, clearly.

Consolidated EBITDA
$0.3→3.1M
2027 → 2031, Phase 1 + flagship
Seed (SAFE) Return
~2.4× / 19%
MOIC / IRR, 5-yr base case
Phase-1 Payback
<1 Yr
CapEx recovered from Year-2 EBITDA
Operating Margin
30→46%
Consolidated, Year 1 → Year 5
5-Year Consolidated Revenue & EBITDA (2027 → 2031)
2027
$1.0M
$0.3M EBITDA
2028
$5.0M
$1.1M EBITDA
2029
$6.3M
$2.0M EBITDA
2030
$7.3M
$2.6M EBITDA
2031
$8.3M
$3.1M EBITDA

All figures recomputed from OROBORIUM Financial Model v7. Revenue is gross consolidated (Phase 1 + flagship); EBITDA is profit after costs and the property-investor distribution. The clean SAFE ($3.5M at a $12M post-money cap) returns ~2.4× / ~19% on the conservative single-flagship base case; the upside is Phase 3 / franchise. Forward-looking projections, not a guarantee of performance.

Use of Funds

Staged capital. Validated deployment.

Two instruments, kept strictly separate. The SAFE is the only dilutive money; the property pre-sales fund the rooms and never touch the equity.

$3.5M
Seed — SAFE · $12M cap
20% discount, MFN, pro-rata for $250K+. Minimum cheque $25K. Funds the platform's permanent equity — land, the Phase-1 clinic, the Phase-2 clinic core, entities and runway.
~$6.0M
Property pre-sales — SPV · non-dilutive
26 units sold to property investors at a 12% yield. Funds the rooms/villas. Optional ~$2M construction debt, secured on land + pre-sales, bridges build timing — repaid from unit recoupment.
Use of the $3.5M SAFE
Phase-2 shared clinic core (equity)40%
Phase-1 lean clinic (retrofit + equipment)17%
Land — secure (deposit + prepaid years)15%
Working capital + contingency14%
Entities, licensing & legal8%
Marketing & pre-opening6%
How the two stack
The $3.5M SAFE funds the permanent platform equity; the ~$6.0M SPV pre-sales fund the rooms separately and are non-dilutive. The SAFE never fronts construction — which is why $3.5M buys ~29% of the whole platform. The $12M cap is a proposal to confirm with counsel / the lead investor.
Roadmap

Phased, deliberate, defensible.

Now — Funding
Late 2026
$3.5M SAFE close
HK HoldCo + PT PMA incorporated
Kura Kura land secured with BTID
First SPV pre-sales open
Bali Luxe Medical integrated
Next — Phase 1 live
Apr 2027
Lean retrofit clinic opens
Profitable in year one
First real revenue reported
Referral agreements signed (BIH, BIMC, Puriva)
Physician advocates onboarded
Scale — Flagship
~2028
Kura Kura flagship opens (20 keys)
Built out to 26 keys
SPV investor units delivered
Helios AI platform integrated
Brand authority established
Horizon
2028+
Southeast Asia expansion
Second market entry
Licensing / franchise model
Remote health platform at scale
Institutional partnerships
Strategic Advantages

The structural advantages that matter.

01
Geography as Leverage
Bali offers Western-quality patient demand at Southeast Asian operating costs. Staff, real estate, and logistics are significantly lower than comparable Western markets, while pricing remains internationally benchmarked.
02
Integrated Model as Moat
The integration of medical, hospitality, and technology into one experience is the primary competitive barrier. Replicating the system requires not just capital but time, partnerships, and operational expertise that cannot be quickly assembled.
03
Existing Patient Flow
Active post-surgery patient referrals from Bali and Australia are already in place. Surgical patients book procedures 6–12 months in advance, giving OROBORIUM measurable forward demand visibility before opening.
04
Regulatory Tailwind
The Indonesian government is actively investing in medical tourism infrastructure and has begun allowing foreign-trained medical practitioners to operate in-country. This directly reduces the regulatory friction of building an internationally-standard clinical team in Bali — a barrier that has constrained competitors.
05
Dual Revenue Architecture
Operating income and asset appreciation run simultaneously. Property investors receive both rental income distributions and capital appreciation — a structure unavailable in purely clinical or purely hospitality models.
06
Physician Equity Programme
By offering a small equity stake from a reserved pool (capped at ~8%, performance-vested) to participating doctors worldwide, OROBORIUM creates a self-reinforcing referral network where physicians are financially aligned with the platform's growth. Each partner becomes a brand ambassador who can authentically refer patients to "their clinic in Bali."
07
Clean, Separated Capital
One dilutive instrument — a $3.5M SAFE — funds the platform's permanent equity. The ~$6M property pre-sales (SPV) fund the rooms separately and are non-dilutive, so the equity never pays for construction. Phase 1 de-risks Phase 2; no single investor carries the full development risk.
08
International Protocols
Medical partnerships with institutions in the US, France, Switzerland, Dubai, and South Korea create a clinical credibility stack that smaller operators cannot replicate without years of relationship-building.
Long-Term Vision

"The standard of care for the global patient will not be set in a hospital. It will be set in an environment designed for recovery."

OROBORIUM is Phase 1 of a platform designed to become the defining brand in premium medical hospitality across Southeast Asia. The Bali facility is proof of concept for a scalable, licenseable system.

Short-Term (2025–2027)
Establish the Bali flagship as a reference site. Validate operating model, build international patient volume, and deliver returns to Phase 1 property investors.
Medium-Term (2027–2029)
Expand to a second Southeast Asian market. Launch the membership and remote health platform. Build licensing framework for third-party operators.
Long-Term (2030+)
OROBORIUM as a recognised category leader in integrated medical hospitality. Institutional partnerships, franchise revenue, and a remote health platform operating across multiple markets.
The Team

Operators, clinicians, and a design pedigree.

Investors back people. The founders combine medical operating experience in Bali, hospitality development, and a design practice that has shipped across four continents.

C. Darius Delaunay-Driquert

Co-Founder & CEO

French entrepreneur, strategist and global designer — early bionic-prosthesis research referenced by DARPA; work from Nike to the White House, shown in museums and biennales.

Ateliersavant · Giving Back · SEED INCIDENT

Sherrie Williams

Co-Founder · Operations & Clinical

Founder of Bali Luxe Medical; ex-KPMG. 2+ years running post-surgery recovery across Bali, with partnerships at every major hospital and a year of forward bookings.

Bali Luxe Medical · Miss Cheri Body & Skin

Anna Kiseleva

Co-Founder & COO

Helped merge two of Russia's national telecom operators, then led the development of major Bali hospitality properties. Construction, operations & guest experience.

ANTA · REVOLT Group · Coco Development

Dr Jacques Durand

Medical Partner

Swiss- & French-licensed longevity MD, 28+ years in clinical operations and C-level healthcare leadership. Co-branded protocols & Scientific Advisory Circle.

Longevity medicine · eHealth · 28 yrs
Advisory Circle
Dr Jasmine Delaunay-Driquert — Cheffe du service de médecine statutaire et de contrôle du CDG69; Vice-Secrétaire Adjointe de la FNAMA
Alexandria Papa — Data & Growth Strategy · Biotech, Pharma & AI
Chris Watkins — RNA biology, glycobiology & human disease; epitranscriptomics, GlycoRNA, chemical biology, sequencing · Harvard Medical

Photography in production. OROBORIUM is in active dialogue with additional doctors, scientists and industry experts regarding their involvement.

Investment Structure

How to participate.

Two primary investment pathways are available — an equity stake in the operating company, and property unit ownership via the accommodation SPV. A third pathway exists for physicians and medical professionals through the equity referral programme.

Instrument
SAFE — $3.5M at $12M post-money cap
Discount / terms
20% · MFN · pro-rata for $250K+
Minimum cheque
$25,000
Seed return (5-yr base)
~2.4× / ~19% IRR
Property units (SPV)
$100K – $480K · 12% / yr
SPV liquidity
Resale after Year 2 — no buyback
Physician pool
≤8% equity, performance-vested
Seeking
Capital · Medical Partners · Hospitality Operators
Investor Profiles
Property Investor (SPV)
Buys shares in a per-unit SPV holding the income rights to one room or villa. A 12%/yr target (8% preferred + up to 4% performance), asset-backed and senior to equity, with 30 nights' use a year. No buyback — liquidity via resale after Year 2. Entry from $100K (Solo Room) to $480K (Family Villa).
Seed Equity (SAFE)
Owns a slice of the whole platform — Phase 1, Phase 2 and Phase 3 — via a $3.5M SAFE at a $12M post-money cap (~29%). ~2.4× / ~19% IRR on the conservative base case; the upside is the platform scaling. Minimum cheque $25K; the SPV pre-sales fund the rooms separately, so your equity never pays for construction.
Medical Partner (Advocacy Pool)
Respected doctors worldwide can earn from a reserved equity pool of up to ~8%, tiered by influence and performance-vested against referred patient revenue — so it costs the P&L nothing and is self-financing through the patients it brings.
Strategic Partner
Medical institutions, hospitality operators, and medical tourism platforms are actively sought as strategic co-investors. Structures are tailored to the nature of the contribution.
Indicative return explorer
$100,000
Drag to size your cheque
Illustrative · not a guarantee
$25K$250K$500K$1M
Seed — % of company
0.83%
at the $12M post-money cap
Seed — 5-yr cash back
$239,000
~2.4× base case
Or — property (SPV) / yr
$12,000
12% target yield
Request Access

The data room & a call.

This briefing is the surface. The full model, cap table, legal structure and data room come in a direct conversation with the team. Tell us how to reach you — we respond on Telegram or WhatsApp.

Investor FAQ

Every question, every type of investor.

Honest answers — seed, property, strategic, visa, clinic, structure. Pick a topic.

A medical-tourism longevity & recovery clinic with luxury hospitality around it, in Bali — a clinic that earns from day one, with rooms and villas sold to property investors and a brand built to scale across Southeast Asia.
Bali offers Western-quality patient demand at Southeast-Asian operating costs, with an established culture of health travel. Kura Kura is a 498-ha Special Economic Zone run by master developer BTID — institutional-grade land, regulatory clarity, SEZ tax incentives, and a curated luxury setting.
Real: the concept, brand, architectural design, the full financial model, the Dr Durand MoU, the GA marketing contract, and Bali Luxe Medical — co-founder Sherrie's post-op recovery operation, running 2+ years with hospital partnerships, integrating into OROBORIUM. Not yet: entities being incorporated, Kura Kura land being secured, Phase-1 site & licences being finalised. We label ambition as ambition.
A slice of the whole company via a SAFE — Phase 1, Phase 2 and any Phase 3. The property pre-sales (SPV) are separate and fund the rooms, so your equity never pays for construction.
Profit-share dividends once profitable (the Phase-1 clinic is cash-positive in year one), and the big one at exit — your equity realised at a sale or refinance in ~4–6 years as Phase 2 builds and the platform scales.
On the conservative single-flagship base case, ~2.4× / ~19% IRR over five years (sensitivity ~1.9–2.4× across a 5–7× exit). A €40K cheque returns ~$103K over five years. If the platform scales as intended, the upside is materially higher — a range, not a promise.
A $3.5M SAFE at a $12M post-money cap (~29%), 20% discount, MFN, pro-rata for $250K+. Minimum cheque $25K. No single investor takes majority — founders retain control.
Shares in a Special Purpose Vehicle holding the income rights to one specific room or villa. All revenue flows to the HoldCo, which pays you a defined yield — like a professionally-managed Bali villa, with a clinic next door driving demand.
A 12% annual target = 8% preferred (paid first, from room income) + up to 4% performance (from the clinic bonus pool, when earned). Not a legal guarantee, but the preferred is structured to be paid first and is well-covered by room income (~1.3× at Year 3). Distributions quarterly.
$100K (a solo room) to $480K (a family villa); smaller investors can pool into one unit. You can resell after Year 2 (company has right of first refusal). No buyback — removed deliberately, so the company carries no large repurchase liability; liquidity is via resale plus the yield. You also get 30 nights' use per year.
We're the premium recovery/longevity layer that sends and receives patients. Surgeons get a high-end recovery destination; clinics get referral flow; platforms get a flagship to list. Integration is the moat — faster to join than to build.
Respected doctors can earn a small equity stake (a reserved pool of up to ~8%, tiered by influence) to refer patients to "their clinic in Bali." It's performance-vested — equity only vests against referred revenue, with clawback if dormant — so it costs the P&L nothing and is self-financing.
Yes, if structured correctly. Indonesia's Investor KITAS gives a foreign shareholder in a PT PMA the right to live in Indonesia and run their business — no separate work permit. OROBORIUM's operating company is a PT PMA, so eligible investors can be structured to qualify. (Immigration rules change — confirm with a licensed advisor.)
Personal shares ≥ IDR 1.125bn (~$70K) in the PT PMA, registered as a Director or Commissioner. So cheques from ~$70K, structured as qualifying PT PMA shares, can support an Investor KITAS (1–2 years, renewable, path toward permanent residency).
Under Health Law 17/2023 + Gov. Reg. 28/2024, foreign specialist doctors can perform medical acts inside a licensed facility — with an STR and SIP, competency evaluation waived for those with 5+ years' experience at recognised institutions. Local licensed doctors deliver routine care from day one; foreign specialists are credentialed in over time.
In-house: IV therapy, HBOT, red-light, diagnostics/labs, recovery, aesthetics, biohacking. Partner/outsourced: stem-cell, some regenerative and surgical-adjacent work, advanced imaging — keeping capital light and regulatory exposure contained.
Hospital and surgeon referral and post-operative transfer relationships — led by co-founder Sherrie, building on Bali Luxe Medical's 2+ years of post-surgery recovery and partnerships with Bali's major hospitals — plus Dr Durand's network and the physician-advocacy programme.
A Hong Kong HoldCo (investor-facing parent) owns an Indonesian PT PMA (operations, licences, land lease); each sold unit sits in its own SPV. One unified entity across both phases — clean separation of operating business, property and land.
The PT PMA pays ~22% Indonesian corporate income tax plus a small dividend withholding to Hong Kong (~5%); HK doesn't tax the foreign-sourced dividends. As a Kura Kura SEZ business, OROBORIUM may qualify for SEZ tax holidays — modelled conservatively at zero benefit.
OROBORIUM licenses the Helios AI app from Ateliersavant (founder-owned), structured arm's-length — a modest flat fee plus a revenue share — fully disclosed as a related-party item, so outside investors can see value isn't being quietly moved out.
Land terms & securing the lease (BTID); licensing/permit timing (gates Phase-1 opening); construction cost/time on Phase 2; slower ramp/occupancy; key-person dependence; and execution complexity. Each has a mitigation — and Phase 1's small, fast footprint is itself a major de-risking step.
The Conversation

The opportunity is structured.
The team is ready.

OROBORIUM is at the stage where the right investors and partners accelerate a platform that is already in motion. If this aligns with your mandate, the next step is a direct conversation.